These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17610813)

  • 1. Parkinson's disease: return of an old prime suspect.
    Sulzer D; Schmitz Y
    Neuron; 2007 Jul; 55(1):8-10. PubMed ID: 17610813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future strategies for the treatment of Parkinson's disease.
    Fahn S
    Adv Neurol; 1993; 60():636-40. PubMed ID: 8420202
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurophysiology: stressful pacemaking.
    Bean BP
    Nature; 2007 Jun; 447(7148):1059-60. PubMed ID: 17597746
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathogenesis of Parkinson's disease.
    Riederer P; Lange KW
    Curr Opin Neurol Neurosurg; 1992 Jun; 5(3):295-300. PubMed ID: 1623255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease.
    Brundin P; Angela Cenci M; Wieloch T
    Exp Neurol; 2006 Sep; 201(1):1-6. PubMed ID: 16806183
    [No Abstract]   [Full Text] [Related]  

  • 8. Death in the substantia nigra: a motor tragedy.
    Esposito E; Di Matteo V; Di Giovanni G
    Expert Rev Neurother; 2007 Jun; 7(6):677-97. PubMed ID: 17563251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Eshel G; Finberg JP; Riederer P
    Adv Neurol; 1993; 60():259-66. PubMed ID: 8380520
    [No Abstract]   [Full Text] [Related]  

  • 10. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease.
    Chan CS; Guzman JN; Ilijic E; Mercer JN; Rick C; Tkatch T; Meredith GE; Surmeier DJ
    Nature; 2007 Jun; 447(7148):1081-6. PubMed ID: 17558391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
    Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
    J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium channels: possible new therapeutic targets in Parkinson's disease.
    Wang Y; Yang PL; Tang JF; Lin JF; Cai XH; Wang XT; Zheng GQ
    Med Hypotheses; 2008 Oct; 71(4):546-50. PubMed ID: 18650029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
    Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M
    Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen and Parkinson's disease.
    Horstink MW; Strijks E; Dluzen DE
    Adv Neurol; 2003; 91():107-14. PubMed ID: 12442669
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of two voltage-gated K+ conductances in substantia nigra dopaminergic neurons.
    Segev D; Korngreen A
    Brain Res; 2007 Oct; 1173():27-35. PubMed ID: 17826751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aging decreases L-type calcium channel currents and pacemaker firing fidelity in substantia nigra dopamine neurons.
    Branch SY; Sharma R; Beckstead MJ
    J Neurosci; 2014 Jul; 34(28):9310-8. PubMed ID: 25009264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.